title: Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.
abstract: Epigenetic modifying enzymes such as histone deacetylases (HDACs), p300, and PRMT1 are recruited by AML1/ETO, the pathogenic protein for t(8;21) acute myeloid leukemia (AML), providing a strong molecular rationale for targeting these enzymes to treat this disease. Although early phase clinical assessment indicated that treatment with HDAC inhibitors (HDACis) may be effective in t(8;21) AML patients, rigorous preclinical studies to identify the molecular and biological events that may determine therapeutic responses have not been performed. Using an AML mouse model driven by expression of AML1/ETO9a (A/E9a), we demonstrated that treatment of mice bearing t(8;21) AML with the HDACi panobinostat caused a robust antileukemic response that did not require functional p53 nor activation of conventional apoptotic pathways. Panobinostat triggered terminal myeloid differentiation via proteasomal degradation of A/E9a. Importantly, conditional A/E9a deletion phenocopied the effects of panobinostat and other HDACis, indicating that destabilization of A/E9a is critical for the antileukemic activity of these agents.
authors.affiliation: Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia;
authors.forename: Michael
authors.initials: M
authors.lastname: Bots
authors.forename: Inge
authors.initials: I
authors.lastname: Verbrugge
authors.forename: Benjamin P
authors.initials: BP
authors.lastname: Martin
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Salmon
authors.forename: Margherita
authors.initials: M
authors.lastname: Ghisi
authors.forename: Adele
authors.initials: A
authors.lastname: Baker
authors.forename: Kym
authors.initials: K
authors.lastname: Stanley
authors.forename: Jake
authors.initials: J
authors.lastname: Shortt
authors.forename: Gert J
authors.initials: GJ
authors.lastname: Ossenkoppele
authors.forename: Johannes
authors.initials: J
authors.lastname: Zuber
authors.forename: Amy R
authors.initials: AR
authors.lastname: Rappaport
authors.forename: Peter
authors.initials: P
authors.lastname: Atadja
authors.forename: Scott W
authors.initials: SW
authors.lastname: Lowe
authors.forename: Ricky W
authors.initials: RW
authors.lastname: Johnstone
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D002478:Cells, Cultured; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics; D004195:Disease Models, Animal; D004622:Embryo, Mammalian; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D000077767:Panobinostat; D000075142:RUNX1 Translocation Partner 1 Protein; D014178:Translocation, Genetic
chemical_list: C107844:AML1-ETO fusion protein, human; D000970:Antineoplastic Agents; D050676:Core Binding Factor Alpha 2 Subunit; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein; D000077767:Panobinostat